Calithera Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-06-01

Employees: 10

Market Cap: $487

Website: http://www.calithera.com

Clinical Trials

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Terminated

Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma
With and Without MyD88 and/or CD79B Mutations

Interventions: Drug: Mivavotinib

First Posted Date: 2022-04-08

Last Posted Date: 2023-04-04

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 2

Registration Number: NCT05319028

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Toledo Clinic Cancer Center, Toledo, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 4 locations

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NFE2L2 Gene Mutation
Squamous Non-Small Cell Neoplasm of Lung
Non-Small Cell Lung Cancer
Squamous Non-small-cell Lung Cancer

Interventions: Drug: sapanisertib

First Posted Date: 2022-03-11

Last Posted Date: 2023-04-04

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 7

Registration Number: NCT05275673

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center - Thoracic, New York, New York, United States
🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa, California, United States

and more 10 locations

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Terminated

Conditions: Non-Small Cell Lung Cancer
NFE2L2 Gene Mutation
KEAP1 Gene Mutation
NRF2 Mutation
Non-Squamous Non-Small Cell Neoplasm of Lung
Non-squamous Non-small-cell Lung Cancer

First Posted Date: 2021-01-07

Last Posted Date: 2023-03-13

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 20

Registration Number: NCT04698681

Locations: 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸
Arizona Oncology Associates - Glendale, Glendale, Arizona, United States
🇺🇸
Rocky Mountain Cancer Centers - Lakewood, Lakewood, Colorado, United States

and more 55 locations

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Phase 1

Completed

Conditions: Cardiac Safety

Interventions: Other: telaglenastat placebo
Other: moxifloxicin
Drug: telaglenastat

First Posted Date: 2020-10-29

Last Posted Date: 2021-03-09

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 30

Registration Number: NCT04607512

Locations: 🇬🇧
Celerion, Belfast, Ireland, United Kingdom

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: Telaglenastat
Drug: Placebo for famotidine
Drug: Famotidine

First Posted Date: 2020-09-07

Last Posted Date: 2021-03-09

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 22

Registration Number: NCT04540965

Locations: 🇦🇺
Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane, Queensland, Australia

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: CB-280
Drug: Placebos

First Posted Date: 2020-02-21

Last Posted Date: 2022-04-13

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 32

Registration Number: NCT04279769

Locations: 🇺🇸
Vermont Lung Center at the University of Vermont Medical Center, Colchester, Vermont, United States
🇨🇦
McGill University Health Center, Montréal, Quebec, Canada
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 17 locations

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer
KEAP1 Gene Mutation
NRF2 Gene Mutation
Non-squamous Non-small-cell Lung Cancer
Non-Squamous Non-Small Cell Neoplasm of Lung
NFE2L2 Gene Mutation

Interventions: Drug: Carboplatin Chemotherapy
Drug: Telaglenastat
Drug: Pemetrexed Chemotherapy
Biological: Pembrolizumab Immunotherapy
Drug: Placebo
Dietary Supplement: Folic acid 400 -1000 μg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Dexamethasone 4 mg

First Posted Date: 2020-02-11

Last Posted Date: 2022-09-21

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 40

Registration Number: NCT04265534

Locations: 🇺🇸
Florida Cancer Specialist - Panhandle (SCRI), Tallahassee, Florida, United States
🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States

and more 90 locations

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1

Completed

Conditions: NSCLC
Solid Tumors
CRC
KRAS Gene Mutation

Interventions: Drug: Telaglenestat (CB-839)
Drug: Palbociclib Oral Capsule or Tablet [Ibrance]

First Posted Date: 2019-05-29

Last Posted Date: 2022-09-19

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 53

Registration Number: NCT03965845

Locations: 🇺🇸
Emory, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Regions Cancer care Center, Saint Paul, Minnesota, United States

and more 7 locations

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1

Terminated

Conditions: RCC
Colorectal Cancer
Solid Tumor
TNBC - Triple-Negative Breast Cancer
CRC
ccRCC
Clear Cell Renal Cell Carcinoma

Interventions: Drug: CB-839
Drug: Talazoparib

First Posted Date: 2019-03-14

Last Posted Date: 2022-02-17

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 33

Registration Number: NCT03875313

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 6 locations

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Phase 1

Withdrawn

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: TAK-659
Drug: NKTR-214

First Posted Date: 2018-12-11

Last Posted Date: 2023-02-08

Lead Sponsor: Calithera Biosciences, Inc

Registration Number: NCT03772288

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇨🇦
Alberta Health Services, Calgary, Alberta, Canada
🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy